# cAMeLot-1 (NCT04811560)

> A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04811560
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Acute Leukemia
- Interventions: Bleximenib
- Enrollment: 420
- Primary outcome: Phase 1: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
- Primary outcome: Phase 1: Number of Participants with AEs by Severity
- Primary outcome: Phase 1: Part 1: Percentage of Participants with Dose-Limiting Toxicity (DLT)
- Primary outcome: Phase 2: Rate of Complete Remission or Complete Remission with Partial Hematologic Recovery (CR/CRh)

## Indexed commentary on cAMeLot-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=camelot-1-nct04811560